Hemostemix Inc at Emerging Growth Conference Transcript
Welcome back, everyone. Sorry about the technical difficulties with ARMT. They will be joining us again in two weeks. But let's introduce our next presenter. We have Hemostemix. It trades on the OTCQB under the symbol HMTXF and on the TSX under the symbol HEM. Founded in 2003, Hemostemix is an autologous stem cell therapy company and a winner of the World Economic Forum Technology Pioneer Award.
The company developed and has published seven peer-reviewed articles about the safety and efficacy of its lead product, ACP-01, as a treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and other conditions of ischemia. Please welcome its Co-founder, President, and CEO, Thomas Smeenk. Welcome back, Thomas, how you doing?
I'm very well, Anna. Thank you. How are you?
Great. That was a mouthful. I hope I pronounced everything correctly.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |